Cited by 43Glioma Diagnosis and TreatmentRadiomics and Machine Learning in Medical ImagingBrain Tumor Detection and Classification

Biologically interpretable multi-task deep learning pipeline predicts molecular alterations, grade, and prognosis in glioma patients

Open access
Wu, Xuewei, Zhang, Shuaitong, Zhang, Zhenyu, He, Zicong, Xu, Zexin, Wang, Weiwei, Jin, Zhe, You, Jingjing +10 more·2024·npj Precision Oncology

Published version of a preprint

Abstract

Deep learning models have been developed for various predictions in glioma; yet, they were constrained by manual segmentation, task-specific design, or a lack of biological interpretation. Herein, we aimed to develop an end-to-end multi-task deep learning (MDL) pipeline that can simultaneously predict molecular alterations and histological grade (auxiliary tasks), as well as prognosis (primary task) in gliomas. Further, we aimed to provide the biological mechanisms underlying the model's predictions. We collected multiscale data including baseline MRI images from 2776 glioma patients across two private (FAHZU and HPPH, n = 1931) and three public datasets (TCGA, n = 213; UCSF, n = 410; and EGD, n = 222). We trained and internally validated the MDL model using our private datasets, and externally validated it using the three public datasets. We used the model-predicted deep prognosis score (DPS) to stratify patients into low-DPS and high-DPS subtypes. Additionally, a radio-multiomics analysis was conducted to elucidate the biological basis of the DPS. In the external validation cohorts, the MDL model achieved average areas under the curve of 0.892-0.903, 0.710-0.894, and 0.850-0.879 for predicting IDH mutation status, 1p/19q co-deletion status, and tumor grade, respectively. Moreover, the MDL model yielded a C-index of 0.723 in the TCGA and 0.671 in the UCSF for the prediction of overall survival. The DPS exhibits significant correlations with activated oncogenic pathways, immune infiltration patterns, specific protein expression, DNA methylation, tumor mutation burden, and tumor-stroma ratio. Accordingly, our work presents an accurate and biologically meaningful tool for predicting molecular subtypes, tumor grade, and survival outcomes in gliomas, which provides personalized clinical decision-making in a global and non-invasive manner.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41698-024-00670-2

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Wu, X., Zhang, S., Zhang, Z., He, Z., Xu, Z., Wang, W., Jin, Z., You, J., Guo, Y., Zhang, L., Huang, W., Wang, F., Liu, X., Yan, D., Cheng, J., Yan, J., Zhang, S., & Zhang, B.
Affiliations
  • First Affiliated Hospital of Jinan University (CN)
  • Beijing Institute of Technology (CN)
  • First Affiliated Hospital of Zhengzhou University (CN)
  • Henan Provincial People's Hospital (CN)
Corresponding author
  • Zhang, Shuaitong
  • Yan, Jing
Venue
npj Precision Oncology
Published
2024-08-16
Volume
8
Issue
1
Pages
181-181
ISSN
2397-768X (ISSN-L)
OpenAlex
W4401638634
Cited by
43
References
56
Citations by year
2026: 20 · 2025: 22 · 2024: 1
FWCI
12.10
Type
journal article
Language
en
Open access
Locations
  • npj Precision Oncology (publishedVersion, cc-by-nc-nd)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • National Natural Science Foundation of China (82227802, 82302306, 202201020022, 2023A03J1038, 82102140, 2023A03J1036)
  • Jinan University
  • National Key Research and Development Program of China (2023YFF1204600, -2022)
Topics
  • Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
  • Life Sciences › Neuroscience › Neurology › Brain Tumor Detection and Classification
Keywords
glioma, multi-task deep learning, outcome prediction, histological grade prediction, molecular alterations, IDH mutation, 1p/19q codeletion, magnetic resonance imaging, overall survival, tumor immune infiltration, DNA methylation, tumor mutational burden, tumor-stroma ratio, oncogenic signaling, biological interpretability

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review